Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 mRNA DC Vaccination to Prevent Relapse in Adult AML
2024-515292-35-00Phase 2Authorised
- Sponsor
- Antwerp University Hospital
- Start
- Oct 2024
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of WT1 mRNA dendritic cell vaccine in acute myeloid leukemia (AML) (2 arms), sponsored by Antwerp University Hospital. Primary endpoint: Overall survival. Planned start Oct 2024; status: authorised.
02
Drugs
WT1 mRNA dendritic cell vaccine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-515292-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515292-35-00.